PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while AXSM shows 288.06% growth. Joel Greenblatt would examine competitive position erosion.
-100.00%
Cost reduction while AXSM shows 229.82% growth. Joel Greenblatt would examine competitive advantage.
100.00%
Gross profit growth below 50% of AXSM's 294.10%. Michael Burry would check for structural issues.
100.00%
Margin expansion exceeding 1.5x AXSM's 1.56%. David Dodd would verify competitive advantages.
7.04%
R&D growth less than half of AXSM's 21.10%. David Dodd would verify if efficiency advantage is sustainable.
-5.63%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.59%
Operating expenses growth less than half of AXSM's 20.26%. David Dodd would verify sustainability.
2.59%
Total costs growth less than half of AXSM's 26.25%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
13.04%
D&A growth while AXSM reduces D&A. John Neff would investigate differences.
-2.44%
EBITDA decline while AXSM shows 91.86% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-2.59%
Operating income decline while AXSM shows 88.27% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-3.66%
Pre-tax income decline while AXSM shows 85.89% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth while AXSM reduces burden. John Neff would investigate differences.
-10.34%
Net income decline while AXSM shows 83.20% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-10.26%
EPS decline while AXSM shows 83.12% growth. Joel Greenblatt would examine position.
-10.26%
Diluted EPS decline while AXSM shows 83.12% growth. Joel Greenblatt would examine position.
0.08%
Share count reduction exceeding 1.5x AXSM's 0.18%. David Dodd would verify capital allocation.
0.08%
Diluted share reduction exceeding 1.5x AXSM's 0.18%. David Dodd would verify capital allocation.